与帕尔沃病毒B19感染相关的溢出约束性心周炎
Sebastian Hasslacher1, Christopher Naoum2, Malcolm Anastasius2
1Department of Cardiology, Concord Repatriation and General Hospital, Hospital Road, Concord, New South Wales, Australia.
JACC. Case reports
|March 21, 2025
概括
帕尔沃病毒B19可以导致成年人收缩性心膜炎,导致心力衰竭. 在标准疗法失败的情况下,低剂量普雷尼索隆有效治疗了这些病例.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 病毒学 病毒学
背景情况:
- 帕尔沃病毒B19是已知的病毒性/非发病性心膜炎的原因.
- 周心炎可以导致溢出-收缩性周心炎,这是一个严重的心脏疾病.
研究的目的:
- 目前有三名成年人患有复杂的流动性约束性帕尔沃病毒B19心膜炎.
- 突出先进成像的诊断作用和特定治疗的有效性.
主要方法:
- 在帕尔沃病毒B19爆发期间,三名成年患者的病例系列.
- 用过胸腔回声心脏成像和心脏磁共振进行诊断.
- 评估了收缩生理学和心周炎症的非侵入性.
主要成果:
- 这三名患者都表现出明显的透静心力衰竭.
- 帕尔沃病毒B19被确定为病原体.
- 通过低剂量普雷迪尼索隆成功治疗.
结论:
- 在成年人患有心膜炎的情况下,应考虑帕尔沃病毒B19,特别是在疫情爆发期间.
- 心声图和心脏MRI对于诊断收缩性心膜炎至关重要.
- 低剂量普雷尼索隆是一种有效的治疗严重的帕尔沃病毒B19诱导的收缩性心膜炎,不响应标准护理.
相关概念视频
01:25Pleural Effusion I: Introduction
376
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
376
01:29Pneumonia II: Pathophysiology
197
The pathophysiology of pneumonia involves the following steps:
197
01:28Pleural Effusion II: Symptoms and Management
144
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
144
01:29Acute Respiratory Failure-V
113
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
113
01:21Acute Respiratory Failure-II
157
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
157
01:28Esophageal Perforation-II: Clinical Manifestations and Management
30
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
30